Evidence map›Paper›PMID 28337318›Full record

ArticleACS medicinal chemistry letters2017

Development of [

Kongzhen Hu, Debasis Patnaik, Thomas Lee Collier, Katarzyna N Lee, Han Gao, Matthew R Swoyer, Benjamin H Rotstein, Hema S Krishnan, Steven H Liang, Jin Wang and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Evaluation of [ACS chemical neuroscience · 2025
    Article
  3. Radiosynthesis and Evaluation ofACS pharmacology & translational science · 2025
    Article
  4. Article
  5. Article
  6. Radiosynthesis and evaluation of a novelAmerican journal of nuclear medicine and molecular imaging · 2024
    Article
  7. PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023
    Review
  8. Article
  9. PET imaging of glycogen synthase kinase-3 in pancreatic cancer xenograft mouse models.American journal of nuclear medicine and molecular imaging · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Kongzhen HuDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Debasis PatnaikChemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology & Psychiatry, Massachusetts General Hospital and Harvard Medical School , Boston Massachusetts 02114, United States.
Thomas Lee CollierGordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School , Boston, Massachusetts 02114, United States.
Katarzyna N LeeDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Han GaoDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Matthew R SwoyerDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Benjamin H RotsteinGordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School , Boston, Massachusetts 02114, United States.
Hema S KrishnanGordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School , Boston, Massachusetts 02114, United States.
Steven H LiangGordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School , Boston, Massachusetts 02114, United States.
Jin WangDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Zhiqiang YanState Key Laboratory of Electroanalytical Chemistry Changchun Institute of Applied Chemistry, Chinese Academy of Sciences , Changchun 130022, Jilin, China.
Jacob M HookerDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, United States.
Neil VasdevGordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School , Boston, Massachusetts 02114, United States.
Stephen J HaggartyChemical Neurobiology Laboratory, Center for Genomic Medicine, Departments of Neurology & Psychiatry, Massachusetts General Hospital and Harvard Medical School , Boston Massachusetts 02114, United States.
Ming-Yu NgaiDepartment of Chemistry, and Institute of Chemical Biology and Drug Discovery, Stony Brook University , Stony Brook, New York 11794-3400, United States.
Harvard University · USStony Brook University · USChinese Academy of Sciences · CN

Funding

Novel Strategies and Reagents for Introduction of Fluorinated GroupsR35GM119652 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Ming-Yu Ngai · 2016 to 2026
$4.8M
Neuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3R01AG054473 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VASDEV, NEIL · 2017 to 2020
$1.7M
New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
NIA NIH HHS R01 AG054473NIDA NIH HHS K01 DA038000NIGMS NIH HHS R35 GM119652
6 · The paper itself

Abstract

Dysregulation of glycogen synthase kinase-3β (GSK-3β) is implicated in the pathogenesis of neurodegenerative and psychiatric disorders. Thus, development of GSK-3β radiotracers for positron emission tomography (PET) imaging is of paramount importance, because such a noninvasive imaging technique would allow better understanding of the link between the activity of GSK-3β and central nervous system disorders in living organisms, and it would enable early detection of the enzyme's aberrant activity. Herein, we report the synthesis and biological evaluation of a series of fluorine-substituted maleimide derivatives that are high-affinity GSK-3β inhibitors. Radiosynthesis of a potential GSK-3β tracer [

Indexed as

Glycogen synthase kinase-3maleimidePET imagingradiofluorination

Identifiers

PMID28337318
PMCPMC5346984
OpenAlexW2585120216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.